Cargando…
The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575818/ https://www.ncbi.nlm.nih.gov/pubmed/36254054 http://dx.doi.org/10.1097/MD.0000000000030739 |
_version_ | 1784811395063218176 |
---|---|
author | Zhang, Miao Sun, Ming-Yue Chen, Qi-Ting Xu, Feng-Qin Chen, Zong-Zheng Wei, Wen-Bo Wang, Rui-Ting Xu, Gui-Peng Yin, Hui-Jun |
author_facet | Zhang, Miao Sun, Ming-Yue Chen, Qi-Ting Xu, Feng-Qin Chen, Zong-Zheng Wei, Wen-Bo Wang, Rui-Ting Xu, Gui-Peng Yin, Hui-Jun |
author_sort | Zhang, Miao |
collection | PubMed |
description | Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available. METHODS: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool. RESULTS: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group. CONCLUSION: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD. |
format | Online Article Text |
id | pubmed-9575818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95758182022-10-17 The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline Zhang, Miao Sun, Ming-Yue Chen, Qi-Ting Xu, Feng-Qin Chen, Zong-Zheng Wei, Wen-Bo Wang, Rui-Ting Xu, Gui-Peng Yin, Hui-Jun Medicine (Baltimore) Research Article Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available. METHODS: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool. RESULTS: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group. CONCLUSION: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575818/ /pubmed/36254054 http://dx.doi.org/10.1097/MD.0000000000030739 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhang, Miao Sun, Ming-Yue Chen, Qi-Ting Xu, Feng-Qin Chen, Zong-Zheng Wei, Wen-Bo Wang, Rui-Ting Xu, Gui-Peng Yin, Hui-Jun The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title | The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title_full | The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title_fullStr | The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title_full_unstemmed | The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title_short | The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline |
title_sort | efficacy of yiqi huoxue method in treating coronary artery disease after percutaneous coronary intervention: a meta-analysis in accordance with prisma guideline |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575818/ https://www.ncbi.nlm.nih.gov/pubmed/36254054 http://dx.doi.org/10.1097/MD.0000000000030739 |
work_keys_str_mv | AT zhangmiao theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT sunmingyue theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT chenqiting theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT xufengqin theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT chenzongzheng theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT weiwenbo theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT wangruiting theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT xuguipeng theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT yinhuijun theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT zhangmiao efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT sunmingyue efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT chenqiting efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT xufengqin efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT chenzongzheng efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT weiwenbo efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT wangruiting efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT xuguipeng efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline AT yinhuijun efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline |